-
2022-501458-13-01
4
2026-04-29
Advanced Stage of Classic Hodgkin Lymphoma
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-523229-16-00
4
2026-04-27
locally advanced basal cell carcinoma patients
-
2025-524542-10-00
4
2026-04-14
Endometrial cancer
-
2025-523085-24-00
5
2026-04-13
Biliary Tract Cancer
-
2025-523657-34-00
5
2026-04-13
Obesity
-
2025-522387-32-00
5
2026-04-10
Uveal Melanoma
-
2025-523013-28-00
4
2026-04-07
Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-521859-23-00
9
2026-03-31
PSMA-positive mCRPC with prior exposure to at least one prior ARPI
-
2024-516544-26-00
4
2026-03-30
acute ischemic stroke
-
2025-522383-33-00
5
2026-03-23
Pulmonary fibrosis
-
2024-518210-81-00
5
2026-03-18
Advanced Hepatocellular Carcinoma
-
2024-519344-32-00
9
2026-03-16
Non-small Cell Lung Cancer
-
2024-518236-36-00
5
2026-03-12
Locoregionally restricted (stage III) small intestinal neuroendocrine
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2025-522713-29-00
5
2026-03-12
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2025-521117-88-00
5
2026-03-11
Cardiovascular Disease
-
2025-522232-13-00
4
2026-03-06
Sepsis-associated acute kidney injury (AKI)
-
2025-521670-34-00
5
2026-03-04
Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or
-
2023-509860-47-00
4
2026-02-20
Ductal carcinoma in situ
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can